血清TFF1、CCL22的表达对口腔癌患者预后的预测价值  

The Prognostic Value of Serum TFF1 and CCL22 Expression in Patients with Oral Cancer

作　　者：赵建敏[1] 陈浩[1] 王凌 刘玉寒 ZHAO Jianmin;CHEN Hao;WANG Ling(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450000)

机构地区：[1]郑州大学第一附属医院,450000

出　　处：《实用癌症杂志》2024年第9期1564-1566,共3页The Practical Journal of Cancer

摘　　要：目的探讨血清三叶因子1(TFF1)、血清CC趋化因子配体22(CCL22)的表达对口腔癌患者预后的预测价值。方法回顾性分析70例口腔癌患者和70例健康体检志愿者的临床资料,将口腔癌患者设为观察组,并根据其预后情况分为预后良好组(50例)和预后不良组(20例);另将健康体检志愿者作为对照组。检测受试者的血清TFF1、CCL22水平,并分析血清TFF1、CCL22表达水平对口腔癌预后的预测价值。结果观察组血清TFF1、CCL22表达水平明显高于对照组(P<0.05);预后不良组血清TFF1、CCL22表达水平明显高于预后良好组(P<0.05)。血清TFF1+CCL22对口腔癌患者预后预测的灵敏度、特异度明显高于血清TFF1与血清CCL22(P<0.05)。结论血清TFF1与CCL22联合预测口腔癌预后具有较高的灵敏度和特异度,可为口腔癌预后的预测提供一定参考。Objective To investigate the prognostic value of serum trefoil factor 1(TFF1)and serum CC chemokine ligand 22(CCL22)expression in patients with oral cancer.Methods The clinical data of 70 patients with oral cancer and 70 healthy volunteers were retrospectively analyzed.The patients with oral cancer were set as the observation group,and were divided into good prognosis group(50 cases)and bad prognosis group(20 cases)according to their prognosis.Healthy volunteers were selected as the control group.Serum TFF1 and CCL22 levels were detected,and the predictive value of serum TFF1 and CCL22 expression levels on prognosis of oral cancer was analyzed.Results The expression levels of serum TFF1 and CCL22 in the observation group were significantly higher than those in the control group(P<0.05).The levels of serum TFF1 and CCL22 in poor prognosis group were significantly higher than those in good prognosis group(P<0.05).The sensitivity and specificity of serum TFF1+CCL22 in predicting prognosis of patients with oral cancer were significantly higher than those of serum TFF1 and serum CCL22(P<0.05).Conclusion The combination of serum TFF1 and CCL22 has high sensitivity and specificity in the detection of oral cancer prognosis,and can effectively predict the prognosis of patients.

关 键 词：口腔癌 血清三叶因子1 血清CC趋化因子配体22 预后 

分 类 号：R739.85[医药卫生—肿瘤]